Tokio Marine Asset Management Co. Ltd. Acquires 5,859 Shares of Pfizer Inc. (NYSE:PFE)

Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 129,407 shares of the biopharmaceutical company’s stock after purchasing an additional 5,859 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Pfizer were worth $3,726,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Briaud Financial Planning Inc bought a new stake in shares of Pfizer during the third quarter worth $30,000. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer during the third quarter worth $34,000. VisionPoint Advisory Group LLC boosted its holdings in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC boosted its holdings in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in Pfizer in the fourth quarter valued at about $36,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE traded down $0.06 during trading hours on Wednesday, hitting $26.26. 24,501,011 shares of the company’s stock traded hands, compared to its average volume of 41,887,898. The firm has a market cap of $148.70 billion, a P/E ratio of 72.94, a P/E/G ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a 52 week low of $25.23 and a 52 week high of $40.37. The business’s fifty day simple moving average is $27.05 and its two-hundred day simple moving average is $28.50. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the company earned $1.14 earnings per share. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.40%. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.